I-Mab to Showcase Innovative Immunotherapies at Jefferies Conference

I-Mab, a prominent biotech company focused on developing cutting-edge immunotherapies for cancer treatment, is set to participate in the upcoming Jefferies Global Healthcare Conference on June 5, 2024. The event, which will be webcasted through I-Mab's Investor Relations website, offers a platform for the company to showcase its innovative solutions in the field of advanced immunotherapy.

Headquartered in Rockville, Maryland, and San Diego, California, I-Mab is at the forefront of revolutionizing cancer treatment through its specialized immunotherapy programs. Individuals keen on learning more about the company's mission and projects can explore their official Investor Relations website. For real-time updates, following I-Mab on LinkedIn and X is recommended. For any specific queries, Tyler Ehler, the Senior Director of Investor Relations, can be contacted at IR@imabbio.com.

As I-Mab gears up to participate in the prestigious Jefferies Global Healthcare Conference, the company's commitment to advancing cancer treatment through innovative immunotherapies remains unwavering. By leveraging its expertise and state-of-the-art facilities, I-Mab continues to make significant strides in the fight against cancer. Stay connected with I-Mab to stay informed about the latest developments in the field of immunotherapy and witness the transformative impact of their groundbreaking initiatives.